Report Year: 2022

Notification from a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR

Read More

Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR

Read More

Summary of the subscription of ordinary bearer series J shares

Read More

Allotment of series J shares

Read More

Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering

Read More

Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Read More

Approval of the prospectus of the Company

Read More

Decision to conduct public offering of J series shares in December 2022

Read More

Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration

Read More

Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE

Read More